INSIGHT FLU005: An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study

Richard T. Davey, Norman Markowitz, John Beigel, Deborah Wentworth, Abdel Babiker, Tauseef Rehman, Robin Dewar, Julia Metcalf, Timothy M. Uyeki, Elizabeth B. Finley, Barbara Standridge, Paul Riska, H. Clifford Lane, Fred Gordin, James D. Neaton, E. Denning, A. Duchene, N. Engen, M. Harrison, K. QuanG. Thompson, Adriana Sanchez, Marie Hoover, Venn Natarajan, H. Preston Holley, John Tierney, Jocelyn Voell, J. Baxter, D. Bigley, P. Coburn, L. Faber, E. Gardner, L. Harlow, M. Jain, L. Makohon, R. Mcconnell, J. Moghe, R. Nahra, B. Omotosho, T. Petersen, H. Polenakovik, S. Rizza, J. Scott, A. Shoen, C. Solorzano, Z. Temesgen, J. Whitaker

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Hemagglutination inhibition (HAI) antibody responses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one patients with influenza during the 2013-2014 season were randomly assigned to receive 0.25 g/kg of hIVIG (n = 16) or placebo (n = 15). For hIVIG recipients, the ratio of geometric mean titers (1 hour after infusion/before infusion) was 4.00 (95% confidence interval [CI], 2.61-6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95% CI, 1.33-2.32) for influenza A(H3N2) and influenza B. Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) versus placebo (n = 8) were higher 1 hour after infusion (3.9 [95% CI, 2.3-6.7]) and sustained through day 3 (2.0 [95% CI, 1.0-4.0]). hIVIG administration significantly increases HAI titer levels among patients with influenza, supporting the need to perform a clinical outcomes study. Clinical trials registration: NCT02008578.

Original languageEnglish (US)
Pages (from-to)574-578
Number of pages5
JournalJournal of Infectious Diseases
Issue number4
StatePublished - Feb 15 2016


  • anti-influenza virus hIVIG
  • antibody titers
  • influenza
  • randomized trial

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'INSIGHT FLU005: An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study'. Together they form a unique fingerprint.

Cite this